Previous Article | Next Article 
Journal of Clinical Microbiology, April 2005, p. 1674-1677, Vol. 43, No. 4
0095-1137/05/$08.00+0 doi:10.1128/JCM.43.4.1674-1677.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.
Utility of Pooled Urine Specimens for Detection of Chlamydia trachomatis and Neisseria gonorrhoeae in Men Attending Public Sexually Transmitted Infection Clinics in Mumbai, India, by PCR
Christina Lindan,1
Meenakshi Mathur,2
Sameer Kumta,2
Hermangi Jerajani,2
Alka Gogate,3
Julius Schachter,4 and
Jeanne Moncada4*
Institute for Global Health, Department of Epidemiology, Center for AIDS Prevention Studies,1
Department of Laboratory Medicine, University of California, San Francisco, California,4
Lokmanya Tilak Municipal Medical College and General Hospital,2
Mumbai District AIDS Control Society, Mumbai, India3
Received 11 October 2004/
Returned for modification 23 November 2004/
Accepted 8 December 2004

ABSTRACT
Pooling urogenital specimens for the detection of
Chlamydia trachomatis and
Neisseria gonorrhoeae by nucleic acid amplification
tests is an attractive alternative to individual testing. As
pooling can reduce the costs of testing as well as labor, it
has been advocated for use in resource-poor settings. However,
it has neither been widely adopted nor evaluated for use in
developing countries. We evaluated the practical use of pooling
first-catch urine (FCU) specimens for the detection of
C. trachomatis and
N. gonorrhoeae from 690 men in Mumbai, India, by PCR. FCU,
urethral smears, and swabs were collected from men seen at two
sexually transmitted infection (STI) clinics. All laboratory
testing was done at the Lokmanya Tilak General Hospital. Gram
stain smears and culture isolation for
N. gonorrhoeae were performed.
Each FCU was tested individually and in pools using the Roche
Amplicor PCR for
C. trachomatis and
N. gonorrhoeae with an internal
control for inhibition. Specimen pools consisted of aliquots
from five consecutively processed FCUs combined into an amplification
tube. An optical density reading of

0.20 indicated a pool for
which subsequent testing of individual samples was required.
Prevalence by PCR on single specimens was 2.2% (15/690) for
C. trachomatis and 5.4% (37/690) for
N. gonorrhoeae. Compared
to individual FCU results, pooling for
C. trachomatis and
N. gonorrhoeae had an overall sensitivity of 96.1% (50/52). Specificity
was 96.5% (83/86) in that three pools required single testing
that failed to identify a positive specimen. Pooling missed
two positive specimens, decreased the inhibition rate, and saved
50.3% of reagent costs. In this resource-limited setting, the
use of pooling to detect
C. trachomatis and
N. gonorrhoeae by
PCR proved to be a simple, accurate, and cost-effective procedure
compared to individual testing.

INTRODUCTION
Nucleic acid amplification tests (NAATs) for detection of
Chlamydia trachomatis and
Neisseria gonorrhoeae are highly sensitive and
specific. Commercially available tests include PCR, Amplicor
(PCR; Roche Molecular Systems, Branchburg, N.J.), strand displacement
amplification, BDProbeTec (SDA; Becton Dickinson Co., Sparks,
Md.), and transcription-mediated amplification, COMBO2 (TMA;
Gen-Probe Inc., San Diego, Calif.) (
16,
17,
23,
24). Despite
their utility, NAATs are expensive and the high cost has been
a deterrent to their routine use in many laboratories. Lisby
et al. evaluated pooling endocervical and urethral samples for
C. trachomatis detection (
13) as a cost-saving strategy. The
concept of pooling involves screening multiple samples in groups.
If any pool is positive, then specimens comprising the pool
are tested individually to identify the true positive and negative
specimens. Because commercially available NAATs are not approved
by the Food and Drug Administration for use with pooled samples,
this procedure must be validated prior to its clinical use.
Several pooling studies have been performed using PCR and LCR
(Abbott Laboratories, Abbott Park, Ill.; product discontinued)
and have focused mainly on
C. trachomatis detection (
3,
4,
8,
9,
11,
19,
20). These studies found the correlation of
C. trachomatis results with individually tested specimens to be excellent.
Pooling urine or swabs for
C. trachomatis detection of samples
from low-prevalence (<5%) populations can reduce the cost
of testing by saving reagents and technician labor. These decreased
costs have also allowed laboratories to achieve a significant
increase in specimen loads. In the United States, approximately
12% of laboratories perform pooling of clinical specimens for
C. trachomatis (
25). Although pooling has been advocated for
use in resource-limited countries for these reasons, its utility
in such settings has not been evaluated.
A major limitation to pooling urogenital specimens for NAATs has been the added time required for all the retesting. First, a repeat test must be performed to identify the individual positive patient in the pool. Then, a repeat test may be performed to confirm the positive specimen. The latter retest is optional and only done if laboratories are following the 2002 Centers for Disease Control and Prevention guidelines' suggestions to confirm positive NAATs (2). If all repeat tests are not completed within the same day, then an increase in turnaround time occurs.
Other areas that require investigation include determining whether pooled samples can be used for N. gonorrhoeae detection. It is also unclear whether pooling increases the likelihood of inhibition. NAATs can be affected by inhibitors (14, 22). Although decreased sensitivity of NAATs with pooled samples has not been reported, internal controls (IC) have not been systematically employed to identify the role of inhibitors.
We evaluated the practical use of testing pooled first-catch urine (FCU) specimens from men in Mumbai, India, as an alternative to individual specimen testing for the detection of C. trachomatis and N. gonorrhoeae by Amplicor PCR. On a subset of men who had urethral discharge, PCR results for N. gonorrhoeae were compared to the reference standard of culture isolation and Gram-stained smears.

MATERIALS AND METHODS
Patient population.
Samples used in this study were obtained from men enrolled in
a randomized controlled trial of a behavioral intervention to
reduce human immunodeficiency virus and STI incidence. The parent
study was approved by the Committee on Human Research at the
University of California San Francisco and the local Institutional
Review Board, which is covered by an National Institutes of
Health Federal Wide Assurance. Informed consent was obtained
from all patients. Subjects were recruited from men seeking
evaluation of STI symptoms or human immunodeficiency virus testing
at two public health clinics: the Sion Lokmanya Tilak General
Hospital and the Mumbai Municipal Corporation STI Clinic in
Mumbai, India. At the time this substudy was conducted, a total
of 1,810 men had been enrolled. As part of the baseline evaluation,
all participants submitted FCU specimens for screening of
C. trachomatis and
N. gonorrhoeae by PCR and swabs of urethral
discharge were obtained from a limited number of symptomatic
men. We evaluated 690 consecutive FCU specimens.
Specimen collection.
All subjects provided 25 to 30 ml of FCU in a sterile collection cup. Swabs of urethral discharge were streaked onto Thayer-Martin plates and onto slides for Gram stain evaluation. N. gonorrhoeae plates were placed in a candle jar at 36°C. Urethral smears were air dried, heat fixed, and Gram stained on site and then placed in slide boxes at room temperature. Prior to processing, FCU specimens were held at 4°C. All specimens were transported to the Lokmanya Tilak General Hospital laboratory at the end of each day, where final testing was performed.
Direct Gram stain.
A positive smear for gonorrhea had gram-negative diplococci with typical morphology identified within or closely associated with polymorphonuclear leukocytes.
N. gonorrhoeae isolation.
Inoculated Thayer-Martin plates were incubated in candle jars at 36°C for 48 h (10). Presumptive N. gonorrhoeae colonies were Gram stained, oxidase tested, and subcultured onto chocolate agar. Pure cultures were confirmed by Gonochek II (EY Laboratories, San Mateo, Calif.).
PCR specimen processing.
Specimens were processed, held at 4°C, and tested within 7 days of collection. Individual urine specimens were prepared up to the point of preamplification and stored until tested in batches. FCUs were swirled in the specimen cup for 10 s. A 500-µl aliquot was placed into a Sarstedt tube along with 500 µl of urine wash buffer. The tube was vortexed and incubated at 37°C for 15 min. FCUs were centrifuged at
12,500 x g for 5 min. The supernatant was discarded and the pellet resuspended in 250 µl of lysis buffer. After a 15-min incubation at room temperature, 250 µl of specimen diluent was added and vortexed and then centrifuged at
12,500 x g for 10 min. These processed specimens were ready for amplification. A pool was made by placing 10 µl of each processed specimen into an amplification vial to create a 5x pool, for a total volume of 50 µl.
PCR assay.
Individual and pooled processed specimens were tested on the same run in accordance with the manufacturer's specifications (16, 24). Briefly, 50-µl volumes of controls, individual specimens, and pooled specimens were placed into reaction tubes along with the master mix containing the C. trachomatis, N. gonorrhoeae, and IC primers. The C. trachomatis primers consisted of a 207-nucleotide sequence within the cryptic plasmid of C. trachomatis. The N. gonorrhoeae primers consisted of a 201-nucleotide sequence within the putative cytosine DNA methyltransferase gene of N. gonorrhoeae. The IC was a DNA plasmid with primer binding regions identical to those of the C. trachomatis target sequence. Samples were thermocycled in a GeneAmp PCR System 9600 (approximately time = 70 min). The program ran 1 cycle for uracil-N-glycosylase activation and denaturation; 35 cycles for target denaturation, primer annealing, and amplicon extension; and a final hold program at 72°C. After thermocycling, amplicons were denatured and hybridized to oligonucleotide probe-specific targets. Three separate detections (C. trachomatis, N. gonorrhoeae, and IC) were done using avidin-horseradish peroxidase as the conjugate and tetramethylbenzidine as the substrate. The plates were read at 450 nm.
PCR cutoff.
A positive result for individual specimen was defined as an optical density (OD) reading of
2.0 for C. trachomatis and
3.5 for N. gonorrhoeae. Equivocal results had OD readings of 0.2 to the cutoff OD for either C. trachomatis or N. gonorrhoeae. N. gonorrhoeae equivocal specimens were repeat tested two times. If two out of three OD readings for N. gonorrhoeae were above
2.0, the specimen was identified as positive. Specimens with an OD of <0.2 on the internal control were considered to be inhibited. As recommended by Kacena et al., an OD cutoff was established for pooled specimens (8). To determine the positive cutoff for a pooled specimen, individual OD readings were compared to pooled specimen OD readings. An OD reading that identified the highest number of positives and had a minimum number of pool retests was selected (Table 1). We determined that an OD cutoff of
0.200 resulted in the best performance profile.
Calculation for sensitivity and specificity.
A true-positive pool had an OD reading of

0.200 that contained
at least one or more specimens with individual
C. trachomatis-
or
N. gonorrhoeae-positive results. A false-negative pool failed
to identify pools that contained individual positive specimens.
A pool with an OD of

0.200 that upon retest of individual specimens
did not yield any positive
C. trachomatis or
N. gonorrhoeae result was defined as a false-positive pool. Because of limited
resources, discrepant analysis of these false-positive pools
was not investigated further.

RESULTS
The prevalence of
C. trachomatis and
N. gonorrhoeae by PCR in
this population was 2.2% (15/690) and 5.4% (37/690), respectively.
Table 2 shows the performance of pooling specimens compared
to individual FCU testing. A total of 138 pools were tested,
of which 15 and 31 were positive for
C. trachomatis and
N. gonorrhoeae,
respectively. Five were positive for both
C. trachomatis and
N. gonorrhoeae. We found that pooling for
C. trachomatis and
N. gonorrhoeae had an overall sensitivity of 96.1% (50/52) compared
to individual results. Specificity was 96.5% (83/86). Pooling
missed two positive specimens, one
C. trachomatis with an OD
reading of 2.146 and one
N. gonorrhoeae with an OD reading of
3.120 (Gram stain or culture was not performed on this asymptomatic
patient). Neither missed positives showed inhibition with the
internal control. There were three (two
C. trachomatis and one
N. gonorrhoeae) presumptive positives pools that were determined
to be false positives upon retesting the individual specimens.
The percentage of specimens that were inhibited decreased from
1.7 to 0% with pooled FCUs.
On the basis of testing for N. gonorrhoeae, pooling resulted in a reagent cost savings of 57.5% (Table 2). Greater savings were seen with testing for C. trachomatis (69.1%). Testing for C. trachomatis and N. gonorrhoeae simultaneously (the usual standard) resulted in a reagent cost savings of 50.3% by pooling specimens.
Only specimens from 31 patients were Gram stained and cultured
for
N. gonorrhoeae, of which 2 were identified as true negatives.
Compared to Gram-stained smear- and culture-positive or Gram-stain
smear- and PCR-positive specimens, PCR of pooled specimens was
highly sensitive 93.1% (27/29). Culture missed 11
N. gonorrhoeae-positive
specimens that pooling identified. Thus, sensitivity for culture
was only 62.1% (18/29). We detected more
N. gonorrhoeae positives
by Gram stain than by culture isolation.

DISCUSSION
Because of the high cost, there are only a limited number of
laboratories using NAATs for the detection of urogenital chlamydia
infection in India. Most laboratories and clinics do not test
for
C. trachomatis. Among those that do; the majority use either
direct fluorescent-antibody assays or enzyme immunoassays or
even serologic tests because they are more affordable. Clearly,
these tests lack both sensitivity and specificity (
12,
18);
however, they continue to be used in India for studies of STI
prevalence, primarily among women (
1,
5,
15). On the basis of
these studies, the prevalence of
C. trachomatis among asymptomatic
women has consistently been reported as being low. Recently,
Singh et al. found that 28% of symptomatic young women in New
Delhi had
C. trachomatis infections when tested with a homebrew
PCR (
21). Whereas in a population-based study using Amplicor
PCR, the prevalence of genital chlamydial infection was reported
to be 1.1% in men and women (
6).
In contrast to studies among women, there are relatively few studies on the prevalence of C. trachomatis in the male Indian population. In our study, we identified a prevalence of 2.2% for C. trachomatis and 5.4% for N. gonorrhoeae in men by PCR testing. Although these numbers are low, similar results were found among slum dwellers in Chennai using PCR testing (D. D. Celentano, Int. Conf. AIDS, abstr. C11007, 2002). As population rates of C. trachomatis are low, pooling of specimens is idea to obtain significant cost savings.
The Amplicor PCR is configured so that C. trachomatis or N. gonorrhoeae can be tested alone or simultaneously. If combined testing is done, then there is an overall reagent cost savings of 50.3% as a result of pooling specimens. Rather than testing 690 specimens, we tested 343 (138 pools and 205 individuals specimens from positive pools). The use of the processed sample as the specimen to be pooled allows a cost savings evaluation that is truly based on the number of tests run. When prevalence rates exceed 10%, the benefits of pooling become less attractive due to the increased cost of retesting pools (11).
Compared to individual FCU results, pooling for C. trachomatis and N. gonorrhoeae had a combined sensitivity of 96.1% (50/52). Specificity was 96.5% (83/86). These results are similar to previous PCR pooling studies (13, 19, 20). However, Morre et al. found slightly better sensitivity and specificity (100% for both) with pools of five FCUs and no observed inhibition in men (19). Their protocol involved pooling unprocessed specimens. We had 93.3% sensitivity and 98.4% specificity with C. trachomatis pooling. In our study, we pooled processed specimens to allow a faster turnaround time in identifying the individual positive specimens within a pool. Laboratories that routinely perform pooling will likely use processed specimens.
Pooling of specimens for detection of N. gonorrhoeae is less commonly used. There is only one published study, by Kacena et al., using LCR testing of female urine samples for N. gonorrhoeae detection (7). Although LCR is no longer available, pooling of samples for N. gonorrhoeae detection using other NAATs theoretically should work. When we compared pooled N. gonorrhoeae testing with culture isolation and Gram-stained smears, the sensitivity of pooling was 93.1%. It is known that PCR is more sensitive than culture (16). In this study, Gram-stained smears identified more cases of N. gonorrhoeae than culture. There were 11 specimens that were smear and PCR positive but culture negative. The lower performance of culture is probably due to difficulties in maintaining an optimum culture system and preparation of quality media in our setting.
There have been some concerns that pooling might increase NAAT inhibition. However, we found the opposite; pooling specimens decreased the inhibition rate from 1.7% (12/690) to 0% (0/138). The observed decrease in inhibition may be due to dilution of inhibitors in pooled samples. The two positive specimens that were missed by pooling were not inhibited. Our rate of inhibition in male FCUs was similar to rates seen in previous PCR clinical evaluations (22, 24).
In conclusion, we found that the use of pooling to detect C. trachomatis and N. gonorrhoeae by PCR is a simple, accurate, and cost-effective procedure compared to individual testing of men attending public STI clinics in Mumbai, India. Once validated in the laboratory, this procedure can be feasible in resource-limited settings. In this setting, further evaluation in samples from women may be warranted since women are the most likely to be screened and differential inhibition rates are seen with female urine.

ACKNOWLEDGMENTS
This work was supported by U.S. National Institute of Allergy
and Infectious Diseases grant RO1-AI43914. PCR test kits were
provided by Roche Molecular Systems (Branchburg, N.J.).
We thank Maninder Setia for collaboration, Sheetal Mungekar for excellent laboratory assistance, Alexandra Hernandez for data management, and our project director, Ellen Stein.

FOOTNOTES
* Corresponding author. Mailing address: Chlamydia Laboratory at SFGH UCSF, Department of Laboratory Medicine, Bldg. 30; Rm. 416, San Francisco, CA 94110. Phone: (415) 824-5115. Fax: (415) 821-8945. E-mail:
jevemo{at}itsa.ucsf.edu.


REFERENCES
1 - Brabin, L., A. Gogate, S. Gogate, A. Karande, R. Khanna, N. Dollimore, K. de Koning, S. Nicholas, and C. A. Hart. 1998. Reproductive tract infections, gynaecological morbidity and HIV seroprevalence among women in Mumbai, India. Bull. W. H. O. 76:277-287.[Medline]
2 - Centers for Disease Control and Prevention. 2002. Screening tests to detect Chlamydia trachomatis and Neisseria gonorrhoeae infections2002. Morb. Mortal. Wkly. Rep. 51:1-38.[Medline]
3 - Clark, A. M., R. Steece, K. Crouse, J. Campbell, S. Zanto, D. Kartchner, S. Mottice, and D. Pettit. 2001. Multisite pooling study using ligase chain reaction in screening for genital Chlamydia trachomatis infections. Sex. Transm. Dis. 28:565-568.[Medline]
4 - Diamant, J., R. Benis, J. Schachter, J. Moncada, F. Pang, H. C. Jha, C. Bhatta, J. S. P. Chaudhary, T. Porco, and T. Lietman. 2001. Pooling of Chlamydia laboratory tests to determine the prevalence of ocular Chlamydia trachomatis infection. Ophthalmic Epidemiol. 8:109-117.[CrossRef][Medline]
5 - Gopalkrishna, V., N. Aggarwal, V. L. Malhotra, R. V. Koranne, V. P. Mohan, A. Mittal, and B. C. Das. 2000. Chlamydia trachomatis and human papillomavirus infection in Indian women with sexually transmitted diseases and cervical precancerous and cancerous lesions. Clin. Microbiol. Infect. 6:88-93.[Medline]
6 - Joyee, A. G., S. P. Thyagarajan, P. Rajendran, R. Hari, P. Balakrishnan, L. Jeyaseelan, T. Kurien, and S. T. D. Study Group. 2004. Chlamydia trachomatis genital infection in apparently healthy adult population of Tamil Nadu, India: a population-based study. Int. J. STD AIDS. 15:51-55.[Abstract/Free Full Text]
7 - Kacena, K. A., S. B. Quinn, S. C. Hartman, T. C. Quinn, and C. A. Gaydos. 1998. Pooling of urine samples for screening for Neisseria gonorrhoeae by ligase chain reaction: accuracy and application. J. Clin. Microbiol. 36:3624-3628.[Abstract/Free Full Text]
8 - Kacena, K. A., S. B. Quinn, M. R. Howell, G. E. Madico, T. C. Quinn, and C. A. Gaydos. 1998. Pooling urine samples for ligase chain reaction screening for genital Chlamydia trachomatis infection in asymptomatic women. J. Clin. Microbiol. 36:481-485.[Abstract/Free Full Text]
9 - Kapala, J., D. Copes, A. Sproston, J. Patel, D. Jang, A. Petrich, J. Mahony, K. Biers, and M. Chernesky. 2000. Pooling cervical swabs and testing by ligase chain reaction are accurate and cost-saving strategies for diagnosis of Chlamydia trachomatis. J. Clin. Microbiol. 38:2480-2483.[Abstract/Free Full Text]
10 - Knapp, J. S., and E. H. Koumans. 1999. Neisseria and Branhamella, p. 586-603. In P. R. Murray, E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken (ed.), Manual of clinical microbiology, 7th ed. ASM Press, Washington, D.C.
11 - Krepel, J., J. Patel, A. Sproston, F. Hopkins, D. Jang, J. Mahony, and M. Chernesky. 1999. The impact on accuracy and cost of ligase chain reaction testing by pooling urine specimens for the diagnosis of Chlamydia trachomatis infections. Sex. Transm. Dis. 26:504-507.[Medline]
12 - Lipkin, E. S., J. V. Moncada, M. A. Shafer, T. E. Wilson, and J. Schachter. 1986. Comparison of monoclonal antibody staining and culture in diagnosing cervical chlamydial infection. J. Clin. Microbiol. 1:114-117.
13 - Lisby, G., J. Scheibel, L. O. Abrahamsson, E. S. Christensen, and S. Paloheimo. 1994. Detection of Chlamydia trachomatis in individual and pooled endocervical and urethral scrapes by a commercially available polymerase chain reaction. APMIS 102:797-800.[Medline]
14 - Mahony, J., S. Chong, D. Jang, K. Luinstra, M. Faught, D. Dalby, J. Sellors, and M. Chernesky. 1998. Urine specimens from pregnant and nonpregnant women inhibitory to amplification of Chlamydia trachomatis nucleic acid by PCR, ligase chain reaction, and transcription-mediated amplification: identification of urinary substances associated with inhibition and removal of inhibitory activity. J. Clin. Microbiol. 36:3122-3126.[Abstract/Free Full Text]
15 - Mania-Pramanik, J., P. K. Meherji, J. S. Gokral, and U. M. Donde. 2001. Chlamydia trachomatis infection in an urban setting. Sex. Transm. Infect. 77:141.[Free Full Text]
16 - Martin, D. H., C. Cammarata, B. Van Der Pol, R. B. Jones, T. C. Quinn, C. A. Gaydos, K. Crotchfelt, J. Schachter, J. Moncada, D. Jungkind, B. Turner, and C. Peyton. 2000. Multicenter evaluation of AMPLICOR and automated COBAS AMPLICOR C. trachomatis/N. gonorrhoeae tests for Neisseria gonorrhoeae. J. Clin. Microbiol. 38:3544-3549.[Abstract/Free Full Text]
17 - Moncada, J., J. Schachter, E. W. Hook III, D. Ferrero, C. Gaydos, T. C. Quinn, D. Willis, A. Weissfeld, and D. H. Martin. 2004. The effect of urine testing in evaluations of the sensitivity of the Gen-Probe Aptima COMBO 2 Assay on endocervical swabs for Chlamydia trachomatis and Neisseria gonorrhoeae: the infected patient standard reduces sensitivity of single site evaluation. Sex. Trans. Dis. 31:273-277.[Medline]
18 - Moncada, J., J. Schachter, G. Bolan, J. Nathan, M. A. Shafer, A. Clark, J. Schwebke, W. Stamm, T. Mroczkowski, Z. Seliborska, and D. H. Martin. 1992. Evaluation of Syva's enzyme immunoassay for the detection of Chlamydia trachomatis in urogenital specimens. Diagn. Microbiol. Infect. Dis. 15:663-668.[CrossRef][Medline]
19 - Morre, S. A., C. J. Meijer, C. Munk, S. Kruger-Kjaer, J. F. Winther, H. O. Jorgensens, and A. J. Van Den Brule. 2000. Pooling of urine specimens for detection of asymptomatic Chlamydia trachomatis infections by PCR in a low-prevalence population: cost-saving strategy for epidemiological studies and screening programs. J. Clin. Microbiol. 38:1679-1680.[Abstract/Free Full Text]
20 - Morre, S. A., R. Van Dijk, C. J. Meijer, A. J. Van Den Brule, S. K. Kjaer, and C. Munk. 2001. Pooling cervical swabs for detection of Chlamydia trachomatis by PCR: sensitivity, dilution, inhibition, and cost-saving aspects. J. Clin. Microbiol. 39:2375-2376.[Free Full Text]
21 - Singh, V., S. Salhan, B. C. Das, and A. Mittal. 2003. Predominance of Chlamydia trachomatis serovars associated with urogenital infections in females in New Delhi, India. J. Clin. Microbiol. 41:2700-2702.[Abstract/Free Full Text]
22 - Toye, B., W. Woods, M. Bobrowska, and K. Ramotar. 1998. Inhibition of PCR in genital and urine specimens submitted for Chlamydia trachomatis testing. J. Clin. Microbiol. 36:2356-2358.[Abstract/Free Full Text]
23 - Van Der Pol, B., D. Ferrero, L. Buck-Barrington, E. Hook III, C. Lenderman, T. Quinn, C. A. Gaydos, J. Lovchik, J. Schachter, J. Moncada, G. Hall, M. J. Tuohy, and R. B. Jones. 2001. Multicenter evaluation of the BDProbeTec system for detection of Chlamydia trachomatis and Neisseria gonorrhoeae in urine specimens, female endocervical swabs, and male urethral swabs. J. Clin. Microbiol. 39:1008-1016.[Abstract/Free Full Text]
24 - Van Der Pol, B., T. C. Quinn, C. A. Gaydos, K. Crotchfelt, J. Schachter, J. Moncada, D. Jungkind, D. H. Martin, B. Turner, C. Peyton, and R. B. Jones. 2000. Multicenter evaluation of the AMPLICOR and automated COBAS AMPLICOR C. trachomatis/N. gonorrhoeae tests for detection of Chlamydia trachomatis. J. Clin. Microbiol. 38:1105-1112.[Abstract/Free Full Text]
25 - Webster Dicker, L., D. J. Mosure, R. Steece, and K. M. Stone. 2004. Laboratory test used in the U.S. public health laboratories for sexually transmitted diseases, 2000. Sex. Transm. Dis. 31:259-264.[Medline]
Journal of Clinical Microbiology, April 2005, p. 1674-1677, Vol. 43, No. 4
0095-1137/05/$08.00+0 doi:10.1128/JCM.43.4.1674-1677.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.